Latest Breaking News On - Two single arm trials - Page 1 : comparemela.com

Flotufolastat fluorine-18 (Posluma), a new PSMA-targeted PET radiopharmaceutical, has been approved in the US for use in prostate cancer.

United statesBrian chapinDrug administrationMd anderson cancer centerBlue earthTwo single arm trialsCancer centerProstate carcinomaAlignant prostate neoplasmProstate cancerAncer prostateAlignant neoplasiaProstate specific antigen psaProstate specific antigenBiologic therapyPositron emission tomography pet